Fairvalue-Calculator Fairvalue-Calculator
EN DE

TaiwanJ Pharmaceuticals Co (6549) Fair Value & Analysis

Healthcare · TW · Market cap 589M TWD

Price7.27 TWD
Fair Value2.66 TWD
Upside-63.4%
Quality95/100
Evidence: Low Range 1.99 TWD – 3.32 TWD

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

TaiwanJ Pharmaceuticals Co (6549) currently trades at 7.27 TWD, while our model-based Fair Value estimate is 2.66 TWD — implying the stock looks roughly 63.4% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

TaiwanJ Pharmaceuticals Co., Ltd., a specialty pharmaceutical company, develops and commercializes small molecules for chronic organ inflammation of metabolic, autoimmune, and infectious etiologies in Taiwan. The company develops JKB-122 and JKB-121; and novel chemical entities for therapy to address chronic liver diseases and allergy/asthma. Its products target various diseases that include liver inflammation/liver fibrosis, non-alcoholic steatohepatitis, non-alcoholic fatty liver disease, autoimmune diseases, asthma, and atopic dermatitis. The company was incorporated in 2011 and is based in Zhubei, Taiwan.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -28% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +1% Alnylam Pharmaceuticals, Inc (ALNY) -82%

Frequently asked questions

Is TaiwanJ Pharmaceuticals Co (6549) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 2.66 TWD versus a price of 7.27 TWD — about −63% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 6549?
Our 21-model fair value for TaiwanJ Pharmaceuticals Co is 2.66 TWD (as of Jun 24, 2026), built from audited fundamentals. The current price is 7.27 TWD.
What is the quality score of 6549?
TaiwanJ Pharmaceuticals Co has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.